• About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Media Library
    • Philogen in the news
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)
Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
    • Publications
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • OncoFAP Radio Conjugates (Imaging)
    • OncoFAP Radio Conjugates (Therapy)
    • OncoFAP-GlyPro-MMAE (Therapy)
    • OncoACP3 (Imaging)
    • OncoACP3 (Therapy)
    • OncoCAIX
  • Press Releases & Media
    • Press Releases
    • Events
    • Philogen in the news
    • Media Library
  • Work with us
    • Careers
    • Partnering

Philogen introduce la piattaforma per il Whistleblowing (Direttiva EU 2019/1937)

Dec 7, 2023 | 2023, Press Releases

Philogen S.p.A. adotta un processo di gestione delle segnalazioni di illeciti riguardanti la Società in linea con le previsioni normative introdotte dal D.lgs. 10 marzo 2023, n. 24 (c.d. “Decreto Whistleblowing”). Per l’invio e la gestione delle segnalazioni, Philogen...

Following the announcements of this morning, Philogen management is inviting you to a Webinar on December 5 at 15:00 GMT | 16:00 CET.

Dec 4, 2023 | 2023, Investors, Past Events

Please contact us at ir@philogen.com or follow the link below to register to the event: https://us06web.zoom.us/webinar/register/1616473304091/WN_UQLuGhWHTtuozv1NvDMvMQ#/registration

Il Consiglio Di Amministrazione approva la Posizione Finanziaria Netta relativa al Terzo Trimestre 2023

Nov 7, 2023 | 2023, Investors, Press Releases

more details

The Board of Directors approves the net financial position for the third quarter of 2023

Nov 7, 2023 | 2023, Investors, Press Releases

more details

23 ottobre 2023 – Aggiornamento sul programma di acquisto di azioni proprie

Oct 23, 2023 | 2023, Investors, Press Releases

More details

Philogen is inviting you to a Webinar on October 18 at 14:00 GMT | 15:00 CET following the exciting announcement on our Phase III trial of Nidlegy™ in locally advanced melanoma

Oct 16, 2023 | 2023, Investors, Past Events

The Webinar will be hosted by Prof. Dr. Dario Neri (CEO and CSO), Dr. Laura Baldi (CFO), Dr. Emanuele Puca (Investor Relations). Please follow the link below to register to the Webinar:...
« Older Entries

Recent Posts

  • Deposito del Verbale dell’Assemblea degli Azionisti
  • Il Consiglio di Amministrazione approva la posizione finanziaria netta relativa al Primo Trimestre 2026
  • The Board of Directors approves the financial position for the first quarter of 2026 (Courtesy English Translation)
  • Philogen to attend the 74th American Society Mass Spectrometry annual conference in San Diego, May 31 – June 4 2026
  • Philogen to attend the Society of Nuclear Medicine and Molecular Imaging (SNMM) annual meeting on May 30 – June 2, 2026

Recent Comments

    Legal

    Privacy Policy

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it